First question is, if you can throw some more color on which exact vertical you face d this operational issue with the client or a client -specific issue impacting your overall revenue? Is it BFSI or Life Sciences?
Sure, Angan. And is this issue completely behind? That is question number one. And question number two is, the net New TCV booking seem to be a bit on the softer side for this quarter. So any further color that you may want to add on that?
Yeah, thanks for the opportunity and Sudhir, you have always been a very numbers focused person and have always been very specific. So in that backdrop this time it's little surprising and curious to understand why you're not coming out with a definitive growth guidance. Like asked by Sandeep earlier, are there some uncertainties which are holding you back? That is number one. And number two, if I understand the correlation map that you are implying, are we talking about high single digit growth kind of an organic growth guidance? And the last question to sort of retain the executives of Cigniti. So are we going to come out with another ESOP plan on top of the recent one, which we had already come out with?
I was just trying to check as to why this time around there is no explicit guidance like you have already been giving.